Introduction
Lipid metabolism pathways under the regulation of LKB1
LKB1-AMPK pathway
LKB1-SIK pathway
PPP affects lipid synthesis by providing NADPH
CD36 promotes lipid uptake and storage
Other downstream lipid regulators of LKB1
Upstream regulated molecules of the LKB1 pathway
SIRT
cAMP/PKA
Hormones and inflammation
LKB1 deficiency-induced abnormal metabolism facilitates tumor progress
ACC-driven lipogenesis supports cell survival and metastasis of tumors
SREBP1 maintains lipid synthesis and tumor cell viability
SCD promotes tumor growth and proliferation
Promoting effect of CPT1A on cancer
ATGL affects tumor energy storage
Application: targeted inhibitors of LKB1 pathways on liver diseases and tumors
Inhibitors activate the LKB1 lipid regulatory pathways
Activators target LKB1 downstream to release liver diseases
Diseases | Factors | Mediated signalling pathways | Effects |
---|---|---|---|
NAFLD | Paeoniflorin α/γ-mangostin | LKB1-AMPK-SREBP1c/ FAS | Inhibiting lipid synthesis and enhancing FAO |
SIRT1-LKB1-AMPK-ACC/CPT1A | |||
ALD | Gentiopicroside | P2X7 receptor/IL1β-LKB1-AMPK-SREBP/ACC/PPARα | Reducing lipogenesis and promoting lipid oxidation |
NASH | DMY | SIRT1-LKB1-AMPK-ACC | Inhibiting lipid synthesis and enhancing FAO |
Liver fibrosis | HIF-1α | lncRNA-H19-LKB1-AMPK | Accelerating FAO and LDs degradation |
Excessive TG | LTA | LKB1-AMPK-ACC1/SREBP1c-FAS | Enhancing oxidation and transport of lipids and reducing the synthesis of TG, cholesterol, and lipid accumulation |
LKB1-AMPK-HMGCR |